ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

Also C-Change new name for National Dialogue on Cancer.

January 16, 2004

Cancer Groups Support Senate FDA Bill; Reform Measure Face Uncertain future

March 1, 1996

FDA Approves Lilly’s Alimta For Metastatic NSCLC

August 27, 2004

NCI Buys Building For PDQ, ICRDB With Donated Money

December 10, 1982

Study: HPV Testing Can Predict Precancers For Nearly Two Decades Following Exam

August 31, 2012

Screening Guidelines Differ Among Major Medical Organizations

January 16, 1998